(RTTNews) - Rocket One Inc. (RKTO) said Tuesday its biotechnology subsidiary Hoth Therapeutics has decided to end its Phase 2a trial of HT-001 early following positive interim efficacy findings. Hoth plans to seek FDA feedback on a potential Phase 3 program.